HLA-DRB5 and non-small cell lung carcinoma: Our study marked the first application of the spatial transcriptomics technology to investigate STAS in NSCLC, suggesting the potential of using HLA-DRB5 expression in the spatial region as a spatial marker for inhibiting STAS, and enriched the research on molecular markers for STAS.